1-2 of 2
Chelsea Johnson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma

Krish Patel, Jean-Marie Michot, Asher Chanan-Khan, Herve Ghesquieres, Kamal Bouabdallah, John C. Byrd, Guillaume Cartron, Craig A. Portell, Melhem Solh, Hervé Tilly, William G. Wierda, Patricia McGovern, Chelsea Johnson, Raman Garcha, Vincent Ribrag, Gabriel Brisou, David Liebowitz, Tycel Phillips
Journal: Blood
Blood (2021) 138 (Supplement 1): 2494.
https://doi.org/10.1182/blood-2021-144350
Published: 2021
Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

Farhad Ravandi, MBBS, Asad Bashey, MD PhD, Wendy Stock, MD, James M. Foran, MD, Raya Mawad, MD, Daniel Egan, MD, William Blum, MD, Allen Yang, MD PhD, Alessandro Pastore, MD, Chelsea Johnson, BSN,RN, Shuo Zheng, Musa Yilmaz, MD, Alice S. Mims, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-134746
Published: 2020